We lower sales by 4% and cut EBIT by SEK 4-12m in 2026E-28E.
* Mixed Q4 but continued operational leverage * Estimates down on adj.
* 24% organic sales growth in Q4 (ABGSCe +27%) Adj.
Q4 sales was SEK 45m (-6% vs. SEB at SEK 48m) corresponding to 24% y/y growth at constant exchange rates (SEBe: 28%).
Our estimate revisions are driven by USD/SEK movements (down almost 7% since our Q3 review) lowering both sales and costs.
* 27% y-o-y organic sales growth in Q4'25e * No change to financial targets expected Q4'25 results due 3 February Q4'25 expectations We bel...
At SEB’s Nordic Seminar, CEO Mark Waugh presented OssDsign to investors just seven days after being appointed.
* Mark Waugh appointed new CEO * Relevant background from orthapaedic industry * Supportive for sentiment Getting ready for the next phase ...
OssDsign this morning announces the appointment of Mark Waugh as new CEO, effective 1 January.
* Major beat on EBIT, but lower sales * Estimates up on adj.
* 35% organic sales growth in Q3 (ABGSCe +38%) Adj.
* 38% y-o-y organic sales growth in Q3'25e * EBIT forecasts cut by 4.
Redeye clarifies the changes in the fair value range.
- Strong growth and gross margin continued in Q2'25 -EBIT revised up by 11% for '25e and 4% for '26e-'27e - Fair value range narrowed to SEK...
Redeye returns with a more in-depth take on the Q2 report.
- Sales beat and higher gross margin - Adj. EBIT +28% vs ABGSCe - Estimates likely to be revised up 8-12% on EBIT '25e Q2 results OssDsign ...
Redeye provides an initial comment on OssDsign’s Q2 report, which came in line with our expectations.
50% y-o-y organic sales growth in Q2'25e EBIT forecasts raised by 1.
Redeye gives its preview on OssDsign’s Q2 2025 report, due on August 19.
Return gives its insights on the recently published PROPEL data.
Redeye embraces the directed share issue of cSEK158m and expects the cash position to suffice until positive cash flow.
Directed share issue and new financial targets Sales SEK 400m by '28e and EBIT/cash flow positive by ~'27e-'28e Fund future growth, clinica...
Redeye returns with a more in-depth take on OssDsign’s Q1 report.
Delivery on both sales and gross margin above expectations EBIT revised up by 11-22% for '25e-'27e Fair value range unchanged at SEK 9-15 S...
Redeye provides an initial comment on OssDsign’s Q1 report, which was mainly in line with our sales forecast but beat our EBIT assumptions (...
Sales beat and higher gross margin Adj. EBIT +45% vs ABGSCe Estimates likely to be revised up 7-10% on EBIT '25e Q1 results OssDsign starts...
Redeye comments on OssDsign’s CEO change, announced earlier this week.
59% y-o-y sales growth for Catalyst in Q1'25e Lower our EBIT forecasts by 12-23% for '25e-'27e Q1'25 results due 6 May Q1'25 expectations W...
Redeye gives its preview on OssDsign’s Q1 2025 report, due on May 6.
Redeye returns with a more in-depth take on OssDsign’s Q4 report.
Sales and gross margin above expectations in Q4 EBIT revised up by 2.
Redeye sees another strong quarter for OssDsign as sales beat our estimates with a continuing robust gross margin.
Beat in Q4 driven by higher sales EBIT +7% vs ABGSCe Estimates likely to be revised up 2-5% on EBIT '25e Q4 results OssDsign delivered a st...
38% y-o-y sales growth for Catalyst in Q4'24e We leave our EBIT forecasts unchanged ahead of the report Q4'24 results due 4 February Q4'24 ...
Redeye gives its preview on OssDsign’s Q3 2024 report, due on February 4.
Redeye returns with a more detailed take on the Q3 report.
Higher sales and gross margin in Q3 EBIT revised up 12.
Redeye sees a solid Q3 report with an improved cash burn, and we welcome the increased gross margin target.
Higher sales growth and gross margin in Q3 EBIT +32% (lower loss) vs ABGSCe Estimates likely to be revised up 5-10% on EBIT '24e Q3 results...
Catalyst to grow 94% in Q3'24e EBIT revised down by 1.
Redeye gives its preview on OssDsign’s Q3 2024 report, due on November 5.
Solid sales but slightly higher opex EBIT revised down by 4.
Redeye returns with a more detailed take on the Q2 report, and we make some estimate changes that push our base case somewhat down.
Redeye sees a quarter demonstrating continued strong sales growth and an OPEX that is in line with our forecast.
Slightly higher opex drives miss on EBIT EBIT (loss) -9% vs ABGSCe Estimates likley to be revised down 2-4% on EBIT '24e Q2 results OssDsig...
Redeye gives its preview on OssDsign’s Q2 2024 report, due on August 20.
- Q2'24 results due 20 August - 142% growth y-o-y for Catalyst, +9.
Redeye returns with a more in-depth take on the Q1 report.
- Solid start in Q1 - Higher sales commissions weigh down on EBIT in '25e-'26e - Fair value revised down to SEK 8-15 (9-16) First quarter wi...
Redeye is encouraged by the strong gross margin in Q1 but at first glance, nothing in the report prompts any significant reconsiderations to...
Sales in line with expectations EBIT (loss) 10% better Estimates likley to be revised up 3-5% on EBIT '24e Q1 results OssDsign reported a s...
Redeye gives its preview on OssDsign’s Q1 2024 report, due on May 14.
Q1'24 results due 14 May 207% growth y-o-y, but limited sequential growth EBIT revised up 2% for '24e-'26e due to FX Q1'24 expectations We ...
Redeye’s initial take on the OPEX in Q4 being temporarily high is bolstered after a deeper dive into the report.
Small miss on underlying PTP in Q4 Higher non-recurring items than expected Fair value range down to SEK 9-16 (9-17) Another quarter with s...
Redeye sees a Q4 with sales coming in according to our estimates, but we note that costs came in higher than expected (both in COGS and OPEX...
Redeye shares its preview of OssDsign’s Q4 2023e results, due on February 6.
Q4'23 results due 6 February Already pre-announced strong sales for Oct-Nov Fully focused US orthobiologics company as of New Year Q4'23 ex...
Redeye embraces the reported data from OssDsign’s TOP FUSION clinical study, and we await further peer-reviewed publication in the intended ...
Redeye is encouraged by the preliminary Q4 (Oct-Nov) sales, and we positively review the sales estimates for Catalyst for 2023e-2025e.
Positive sales update for Q4 Oct-Nov sales of 25.2m (ABGSCe Q4 SEK 24) Implied upside of 13% to our FY '23e sales estimates Trading update ...
Catalyst växte med 155% under Q3’23 OssDsigns nettoomsättning för det tredje kvartalet 2023 uppgick till 31,7 mkr, vilket motsvarar 81% i ti...
Redeye returns with more insights on the Q3 report, and we continue to feel confident in OssDsign’s capabilities in increasing Catalyst sale...
74% FX-adj. sales growth in Q3, mainly driven by Catalyst Balance sheet strengthened through directed share issue Fair value range raised to...
Redeye provides its initial comment on OssDsign’s Q3 report.
Redeye shares its preview of OssDsign’s Q3 2023e results, due November 21.
Redeye returns with a more in-depth take on the discontinuation of Cranial.
Strategiskifte OssDsign kommer nu att fokusera enbart på kommersialiseringen av OssDsign Catalyst i USA, som utgör mer än 70% av den globala...
Value accretive shift in strategy Directed share issue of SEK 150m Fair value range up to SEK 9-15 (from 6-15) Shift in strategy We believe...
Redeye welcomes the discontinuation of the cranial implant, freeing up resources for the company to focus entirely on its Catalyst product.
